Universal Vision Biotechnology Management
Management criteria checks 2/4
Universal Vision Biotechnology's CEO is Pi-Jung Lin, appointed in Jun 2001, has a tenure of 23.58 years. directly owns 22.75% of the company’s shares, worth NT$3.91B. The average tenure of the management team and the board of directors is 12.3 years and 6.6 years respectively.
Key information
Pi-Jung Lin
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 23.6yrs |
| CEO ownership | 22.7% |
| Management average tenure | 12.3yrs |
| Board average tenure | 6.6yrs |
Recent management updates
Recent updates
Universal Vision Biotechnology (GTSM:3218) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 03
The Case For Universal Vision Biotechnology Co., Ltd. (GTSM:3218): Could It Be A Nice Addition To Your Dividend Portfolio?
Mar 26Universal Vision Biotechnology Co., Ltd. (GTSM:3218) Shares Could Be 39% Below Their Intrinsic Value Estimate
Mar 08The 22% Return On Capital At Universal Vision Biotechnology (GTSM:3218) Got Our Attention
Feb 07Universal Vision Biotechnology Co., Ltd. (GTSM:3218) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Jan 17
Universal Vision Biotechnology (GTSM:3218) Seems To Use Debt Rather Sparingly
Dec 27Estimating The Fair Value Of Universal Vision Biotechnology Co., Ltd. (GTSM:3218)
Dec 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | NT$1b |
| Jun 30 2024 | n/a | n/a | NT$1b |
| Mar 31 2024 | n/a | n/a | NT$1b |
| Dec 31 2023 | n/a | n/a | NT$1b |
| Sep 30 2023 | n/a | n/a | NT$1b |
| Jun 30 2023 | n/a | n/a | NT$976m |
| Mar 31 2023 | n/a | n/a | NT$903m |
| Dec 31 2022 | n/a | n/a | NT$851m |
| Sep 30 2022 | n/a | n/a | NT$791m |
| Jun 30 2022 | n/a | n/a | NT$719m |
| Mar 31 2022 | n/a | n/a | NT$659m |
| Dec 31 2021 | NT$3m | NT$965k | NT$595m |
Compensation vs Market: Insufficient data to establish whether Pi-Jung's total compensation is reasonable compared to companies of similar size in the TW market.
Compensation vs Earnings: Insufficient data to compare Pi-Jung's compensation with company performance.
CEO
Pi-Jung Lin
23.6yrs
Tenure
NT$2,925,000
Compensation
Mr. Pi-Jung Lin serves as a Director of Universal Vision Biotechnology Co., Ltd. since June 2, 2003 and is its Chief Technology Officer since June 1, 2001. He is a Founder of Universal Vision Biotechnology...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 23.6yrs | NT$2.93m | 22.75% NT$ 3.9b | |
| Director of Finance & Accounting | 2.3yrs | no data | no data | |
| Director of Human Resources & Administration Division | 4.7yrs | no data | no data | |
| Director of Marketing Division | 12.3yrs | no data | no data | |
| Chief Auditor of Audit Office | 15yrs | no data | no data |
12.3yrs
Average Tenure
Experienced Management: 3218's management team is seasoned and experienced (12.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 21.6yrs | NT$2.93m | 22.75% NT$ 3.9b | |
| Director | less than a year | no data | no data | |
| Representative Chairman of Board | 12.6yrs | NT$4.09m | 0.0034% NT$ 588.2k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 12.6yrs | NT$2.05m | no data | |
| Independent Director | 6.6yrs | NT$2.05m | 0.014% NT$ 2.5m | |
| Independent Director | 3.4yrs | NT$951.00k | no data | |
| Representative Director | 6.6yrs | NT$1.90m | no data | |
| Representative Director | 6.6yrs | NT$1.90m | no data |
6.6yrs
Average Tenure
Experienced Board: 3218's board of directors are considered experienced (6.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 12:31 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Universal Vision Biotechnology Co., Ltd. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Regina Lee | Capital Securities Corporation |
| Hui-Chao Hsu | Citigroup Inc |
| Corinne Jian | Macquarie Research |